Lupin's US launches will drive growth in FY13; Q3 sales up 22%
This article was originally published in Scrip
Nilesh Gupta, Lupin's group president, told Scrip that the company anticipates about 25 generic launches in the US in the next fiscal year, roughly half of these in the 'fairly lucrative' oral contraceptives segment. In the third quarter, Lupin launched three oral contraceptive products in the US, including the authorised generic for Femcon Fe from Warner Chilcott which has garnered a share of about 15-20%. Currently half of Lupin's 32 marketed generic products in the US rank number one by market share and 30 of the 32 are in the top three by market share, the company said. The company received seven ANDA approvals in the quarter including those for zidovudine, minocylcine ER, duloxetine DR and fenofibrate.
You may also be interested in...
India clears Opdivo patent, turning down pre-grant representations from four opposing parties including Dr Reddy's. The patent office rejected the opponents' arguments including those around obviousness and "inherent anticipation."
Private equity group Carlyle has acquired 20% of Piramal's pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.
Fujifilm Toyama seals three-way deal to accelerate the development and global supply of favipiravir, close on the heels of the arrival of a generic version of the antiviral in India under restricted emergency use for the treatment of COVID-19.